Redundant systematic reviews on the same topic in surgery: a study protocol for a meta-epidemiological investigation by Katsura, Morihiro et al.
TitleRedundant systematic reviews on the same topic in surgery: astudy protocol for a meta-epidemiological investigation
Author(s)Katsura, Morihiro; Kuriyama, Akira; Tada, Masafumi;Yamamoto, Kazumichi; Furukawa, Toshi A




© Article author(s) (or their employer(s) unless otherwise
stated in the text of the article) 2017. All rights reserved. No
commercial use is permitted unless otherwise expressly
granted. This is an Open Access article distributed in
accordance with the Creative Commons Attribution Non
Commercial (CC BY-NC 4.0) license, which permits others to
distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different






 1Katsura M, et al. BMJ Open 2017;7:e017411. doi:10.1136/bmjopen-2017-017411
Open Access 
AbstrAct
Introduction We are witnessing an explosive increase 
in redundant and overlapping publications of systematic 
reviews and meta-analyses (SRs/MAs) on the same topic, 
which often present conflicting results and interpretations, 
in the current medical literature. They represent wasted 
efforts on the part of investigators and peer reviewers 
and may confuse and possibly mislead clinicians and 
policymakers. Here, we present a protocol for a meta-
epidemiological investigation to describe how often there 
are overlapping SRs/MAs on the same topic, to assess the 
quality of these multiple publications, and to investigate 
the causes of discrepant results between multiple SRs/
MAs in the field of major surgery.
Methods and analysis We will use MEDLINE/PubMed 
to identify all SRs/MAs of randomised controlled trials 
(RCTs) published in 2015 regarding major surgical 
interventions. After identifying the ‘benchmark’ SRs/MAs 
published in 2015, a process of screening in MEDLINE 
will be carried out to identify the previous SRs/MAs of 
RCTs on the same topic that were published within 5 
years of the ‘benchmark’ SRs/MAs. We will tabulate the 
number of previous SRs/MAs on the same topic of RCTs, 
and then describe their variations in numbers of RCTs 
included, sample sizes, effect size estimates and other 
characteristics. We will also assess the differences in 
quality of each SR/MA using A Measurement Tool to Assess 
Systematic Reviews (AMSTAR) score. Finally, we will 
investigate the potential reasons to explain the discrepant 
results between multiple SRs/MAs.
Ethics and dissemination No formal ethical approval and 
informed consent are required because this study will not 
collect primary individual data. The intended audiences of 
the findings include clinicians, healthcare researchers and 
policymakers. We will publish our findings as a scientific 
report in a peer-reviewed journal.
trial registration number In PROSPERO 
CRD42017059077, March 2017.
IntroductIon
Description of the condition
In recent years, the number of published 
systematic reviews (SRs) and meta-analyses 
(MAs) have been increasing explosively in 
many medical fields.1–4 When a small number 
of randomised control trials (RCTs) of new 
research questions are published, new SRs/
MAs soon follow these RCTs. Indeed, it is 
becoming more and more difficult to find 
a new research question that nobody has 
examined as a SR article in medical jour-
nals. Furthermore, many topics addressed by 
SRs/MAs often overlap with each other 
entirely or partially, and instances have been 
reported where more than 10 SRs/MAs were 
published on a single topic in a limited span 
of time.2 3 These potentially redundant publi-
cations may represent duplicated efforts for 
researchers, peer reviewers and editors of the 
medical journals.
The picture is even more confusing and 
distressing for readers of the medical litera-
ture. Some previous studies have shown that 
the numbers of pooled RCTs that included 
patients’ sample sizes are quite different 
across SRs/MAs on the same topic.2 3 5–10 It 
is then a natural consequence that there 
are discrepancies between results of SRs/
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Protocol
strengths and limitations of this study
 ► This meta-epidemiological study is the first to 
focus on the cause of discrepant results between 
multiple overlapping systematic reviews and meta-
analyses (SRs/MAs) on many and unspecified topics 
in surgery.
 ► Our study will provide a more clear assessment of 
the results by minimising the impact of industry 
sponsorship that would be typical of pharmacological 
interventions, because our study will mainly examine 
those of surgical interventions.
 ► Judging whether the topic is identical or different 
according to the similarity of the research question 
may be difficult.
 ► The time lag between manuscript submission 
dates and its official publication dates should be 
considered as an important factor that might affect 
the proportion of all available randomised controlled 
trials that are included in a particular SR/MA.
 ► We will perform the article search using a single 
database (MEDLINE via PubMed) to identify SRs/
MAs.
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MAs; different effect sizes, with different statistical preci-
sion, and even different directions of effect have been 
reported.2 3 5–10 Such conflicting results can confuse and 
sometimes mislead clinicians, who are required to make 
a decision and choose among all competing treatments. 
In addition, previous meta-epidemiological studies have 
reported that some SRs/MAs actually omitted and did 
not cite previous review articles even though the research 
question was identical.4 8
Why it is important to do this review
How do we explain these discrepant results between 
multiple SRs/MAs on the same topic? Some possible 
explanations for these problems have been suggested, 
such as the differences of each review’s eligibility criteria, 
the publication of updated versions, inclusion or exclu-
sion of unpublished data, different databases searched, 
search dates, language restrictions, errors in data 
extraction and statistical methods for data synthesis.2–10 
However, it is unclear which factor is the most influ-
ential and whether there are other unknown causes. 
Some recent studies have reported that rapid growth of 
SRs/MAs regarding antidepressant medications was 
linked to industry sponsorship.1 11 In the field of major 
surgery, as far as the present authors are aware, there has 
been no meta-epidemiological study that has examined 
the problem of redundant and overlapping MAs.
objectives
The primary objectives of this study are (1) to describe 
how often SRs/MAs of RCTs that were published almost 
at the same time on the same topic overlap with one 
another and (2) to investigate the cause of discrepant 
results between multiple SRs/MAs. In addition, we will 
sequentially assess the quality of these multiple SRs/
MAs. The hypothesis of the proposed study is that there 
are many redundant overlapping publications with 
conflicting results and various qualities, which repre-
sent wasted efforts for investigators and peer reviewers 
and may well mislead the clinicians and policymakers in 





We will select the studies according to the following inclu-
sion and exclusion criteria.
Inclusion criteria
1. SRs/MAs of only RCTs.
2. Study populations of RCTs are patients that 
underwent chest and abdominal surgeries. We define 
chest surgery as any surgical procedure involving 
intrathoracic organs (eg, surgery for coronary artery 
bypass graft and surgery for lung, mediastinal and 
pleural diseases). We define abdominal surgery as 
deliberate breach of peritoneum or retroperitoneum, 
including gastrointestinal surgery, abdominal 
aortic surgery, urological surgery and obstetrics and 
gynaecological surgery.
3. Interventions (or comparisons) of RCTs are any 
surgical interventions that were abdominal or chest 
procedures performed in the operating room. We will 
include both comparisons of surgical versus surgical 
interventions and comparisons of surgical versus non-
pharmacological interventions.
4. We will include any outcomes reported by the 
SRs/MAs, including continuous and dichotomous 
outcomes.
Exclusion criteria
1. SRs/MAs that include both RCTs and observational 
studies.
2. SRs/MAs that include both RCTs and quasi-RCTs.
3. Network MAs.
4. Individual-patient data MAs.
5. Interventions (or comparisons) of RCTs are any 
pharmacological interventions.
Search strategy and study selection
First, we will use the MEDLINE (via PubMed) database 
to identify recent SRs/MAs of RCTs published in 2015 
in the field of major surgical interventions. We will use 
a straightforward combination of Medical Subject Head-
ings terms relevant to SRs and surgery: (systematic[sb] 
AND (‘surgery’ [subheading] AND 2015 [dp]) without 
language restriction. We will exclude studies that do not 
meet our eligibility criteria based on titles and abstracts, 
and then read the full text to decide whether papers with 
potentially relevant titles and abstracts meet our eligibility 
criteria. Those that meet our eligibility criteria at this 
point will be termed as the ‘benchmark’ SRs/MAs and 
topics. We show their eligibility criteria above. If there 
are more than two same/similar topics in 2015, we will 
set the broadest one regarding study populations as the 
‘benchmark’ topic. For example, when study populations 
of study A are a subgroup of study B, we will set study B as 
a ‘benchmark’ SR/MA or topic.
Second, we will conduct screening in MEDLINE to 
identify similar previous SRs/MAs of RCTs on the same 
topics that were published from 2011 to 2015. To be 
more specific, after identifying ‘benchmark’ SRs/MAs 
of RCTs published in 2015, we will carry out this process 
of screening in MEDLINE to identify the previous over-
lapping MAs/SRs of RCTs on the same topic that were 
published within 5 years of the ‘benchmark’ SRs/MAs 
and bibliographies of included articles, according to the 
titles and abstracts. The reviews identified during the 
bench marking process will be used to identify relevant 
keywords and then index terms to devise a complete 
PubMed/MEDLINE search strategy to locate relevant 
SRs/MAs published between 2011 and 2015. Refer-
ence lists of review articles and original RCTs will be 
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considered as additional sources of information. SRs/
MAs will be selected according to the population, inter-
vention and comparator only. In other words, we will not 
place restrictions on outcomes, as long as the SRs/MAs 
share common study populations, surgical interventions 
and comparators. We will not place language restrictions 
at this stage, either.
Two pairs of two trained researchers will perform the 
title and abstract review, full-paper screening and data 
extraction. Two researchers will independently evaluate if 
a SR/MA is eligible and if the research question is similar 
to that of the ‘benchmark’ review. Any disagreements will 
be resolved through discussions or through involvement 
of a third researcher.
data extraction and management
Two researchers will independently read each full paper 
and extract data in duplicate using a standardised form to 
ensure consistency of extracted data for each study. The 
following information will be extracted:
1. Journal and study characteristics (lead author’s name 
and country affiliation, official publication year, 
journal name and journal impact factor, the presence 
or absence of methodologist in the list of coauthors).
2. Search methodology (the name and number of 
databases searched, date of last search, language 
restriction and restrictions on publication status).
3. Research question of SRs/MAs (PICO: participant 
characteristics, intervention/comparison details and 
outcome measures).
4. Characteristics of SRs/MAs (number of eligible RCTs, 
sample size, effect size, statistical approach (eg, fixed 
effects vs random effects model), citation of previous 
SRs/MAs and the presence or absence of industry 
funding).
We will resolve any disagreement in consultation with 
the third investigator of the review team.
data analysis
Descriptive statistics will be used to summarise charac-
teristics of each of the included SRs/MAs on the same 
research question. We will tabulate the number of 
previous SRs/MAs of RCTs on the same research ques-
tion that were published within 5 years of publication of 
the ‘benchmark’ SRs/MAs. Next for each topic, we will 
describe the differences in number of RCTs included, 
sample size, effect size and variability between SRs/MAs. 
We will compare the coverage ratio of all RCTs that were 
published until the publication year of each SR/MA. The 
difference in treatment effect estimates, expressed either 
as OR or standardised mean difference (SMD), will be 
compared between each of the older MAs and the latest 
MA. If the original studies used other efficacy indexes 
and provided sufficient data for the calculations, we will 
convert them into ORs or SMDs. We will calculate relative 
OR or the difference in SMDs and their 95% CIs, as were 
done in some previous meta-epidemiological studies.12 13
We will also assess the difference in quality of each 
SR/MA on the same research question. To evaluate 
study quality, we will use ‘A Measurement Tool to Assess 
Systematic Reviews’ (AMSTAR)14 instrument. Regarding 
the AMSTAR score, reported points will be assigned as 
follows: yes=1, no=0, not applicable=1.15 The difference 
in study quality, expressed as AMSTAR scores, will be 
compared between each SR/MA.
Finally, we will investigate the potential reasons to 
explain the discrepant results, if any, between multiple 
SRs/MAs. We will evaluate which factors (eg, compre-
hensiveness of search, number of eligible RCTs, statistical 
approach and industry funding) influence these differ-
ences and whether there are some other unexpected 
causes. Thus, we might conduct additional exploratory 
analyses.
Statistical analyses will be two sided, with a p value of 
0.05 indicating statistical significance. All analyses will be 
performed using Stata/SE 11 (StataCorp).
EthIcs And dIssEMInAtIon
This meta-epidemiological study does not require ethical 
approval. We will publish the findings of this study in a 
peer-reviewed scientific journal and present them at 
scientific conferences. The results of this research will be 
disseminated electronically or in print, as well as among 
internet communities.
dIscussIon
Strengths and limitations of study
We have presented the study protocol for a meta-epi-
demiological investigation with respect to redundant 
publications of overlapping SRs/MAs on the same topic 
in major surgery. Our study has several strengths. First, 
most previous studies were restricted to some specific 
topics.2 3 6–11 To our knowledge, this is the first effort 
to investigate the cause of discrepant results between 
multiple SRs/MAs on many and unspecified topics all 
together. Readers of our research can more confidently 
generalise our findings. Second, unlike most previous 
studies that evaluated the recent SRs/MAs of pharma-
cological treatments,3 4 7 11 our study will examine those 
of surgical interventions. Thus, our study will provide a 
more clear assessment of the results by minimising the 
impact of industry sponsorship that would be typical of 
pharmacological treatments. Third, we will employ a 
well-designed systematic approach, including the use 
of standardised and pilot-tested screening with a well-
trained research team.
There are, however, some limitations to our study. 
First, judging whether the topic is identical or different 
according to the similarity of the research question 
(and PICO) may be difficult. In order to overcome this 
problem, we will perform several pilot tests for selecting 
SRs/MAs and will operationalise a consensus procedure to 
judge the similarity of the research question in our review 
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team. Second, we will search only MEDLINE/PubMed for 
SRs/MAs of surgical intervention trials. To assess 
effects of a certain intervention, we would have to have 
a comprehensive dataset of all heretofore conducted 
RCTs, published or unpublished, and we need to search 
all possibly relevant databases and beyond. However, the 
focus of our review is the likely redundancy and contra-
dictions among the SRs in surgery that can be accessed 
to and therefore used by clinicians and policymakers. We 
therefore chose the source that is most often used by clini-
cians worldwide, namely MEDLINE/PubMed. We might 
therefore be missing some additional relevant SRs/MAs 
about a given topic. This could potentially indicate that 
overlapping of SRs/MAs on a single topic is more redun-
dant than we will record. However, limiting the scope of 
the review to MEDLINE/PubMed will make our study 
more applicable to the real world use of the SRs/MAs by 
the clinicians. Third, publication speed may vary across 
journals: the time lag between manuscript submission 
(or acceptance) dates and its official publication dates 
should be considered as an important factor that might 
affect the coverage ratio of all RCTs that were published 
until the publication year/month of the SRs/MAs on the 
certain topic.16 17 We therefore plan to perform sensitivity 
analyses, if possible, by using date of the last database 
search to check for the robustness of the observed find-
ings. Fourth, the findings from this review would not be 
directly generalisable to reviews including both RCTs and 
non-RCTs, which would have greater sources of heteroge-
neity in their study conclusions.
Despite possible methodological limitations, our 
findings of the proposed research may have important 
implications for researchers and clinical decision-makers. 
The high variability in results between SRs/MAs on the 
same topic may indicate a potential risk of the accepted 
wisdom about the hierarchy of evidence levels.
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